Key Points
- Suvretta Capital Management, L purchased 10,215 shares of Benitec on Dec. 18 at $11.24 and, together with additional buys on Dec. 19 and Dec. 22 and a large Nov. 7 acquisition of 1,481,481 shares (~$20M), now holds 9,546,875 shares valued at about $107.3M.
- Benitec (NASDAQ: BNTC) trades around $12.35 with a market cap of $418M; analysts list an average rating of “Moderate Buy” and an average price target of $26.25, and the company recently reported an EPS of -$0.22 that beat estimates.
Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) Director Suvretta Capital Management, L purchased 10,215 shares of the business's stock in a transaction dated Thursday, December 18th. The shares were purchased at an average cost of $11.24 per share, with a total value of $114,816.60. Following the acquisition, the director owned 9,546,875 shares in the company, valued at $107,306,875. This trade represents a 0.11% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.
Suvretta Capital Management, L also recently made the following trade(s):
- On Monday, December 22nd, Suvretta Capital Management, L bought 19,542 shares of Benitec Biopharma stock. The shares were acquired at an average cost of $12.08 per share, with a total value of $236,067.36.
- On Friday, December 19th, Suvretta Capital Management, L purchased 16,384 shares of Benitec Biopharma stock. The shares were bought at an average price of $11.48 per share, with a total value of $188,088.32.
- On Friday, November 7th, Suvretta Capital Management, L bought 1,481,481 shares of Benitec Biopharma stock. The stock was purchased at an average price of $13.50 per share, with a total value of $19,999,993.50.
Benitec Biopharma Price Performance
NASDAQ:BNTC opened at $12.35 on Tuesday. The firm's 50 day simple moving average is $13.81 and its 200 day simple moving average is $13.46. Benitec Biopharma Limited has a one year low of $9.70 and a one year high of $17.15. The company has a market cap of $418.17 million, a PE ratio of -10.21 and a beta of 0.20.
Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its quarterly earnings data on Friday, November 14th. The biotechnology company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.13. Equities research analysts expect that Benitec Biopharma Limited will post -1.48 EPS for the current year.
Institutional Investors Weigh In On Benitec Biopharma
Hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its holdings in Benitec Biopharma by 44.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 904 shares during the period. MYDA Advisors LLC grew its stake in shares of Benitec Biopharma by 4.0% in the first quarter. MYDA Advisors LLC now owns 52,000 shares of the biotechnology company's stock worth $677,000 after purchasing an additional 2,000 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new stake in Benitec Biopharma in the 2nd quarter worth approximately $38,000. Russell Investments Group Ltd. bought a new position in Benitec Biopharma in the 3rd quarter worth $79,000. Finally, Bank of America Corp DE raised its stake in Benitec Biopharma by 2,255.8% in the second quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company's stock worth $80,000 after buying an additional 6,587 shares in the last quarter. 52.19% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
BNTC has been the topic of a number of research analyst reports. JMP Securities set a $22.00 price objective on shares of Benitec Biopharma in a research report on Tuesday, November 4th. HC Wainwright set a $32.00 target price on Benitec Biopharma and gave the company a "buy" rating in a report on Monday, November 24th. Citigroup restated an "outperform" rating on shares of Benitec Biopharma in a research note on Tuesday, November 4th. Oppenheimer reissued an "outperform" rating and set a $29.00 target price (down previously from $35.00) on shares of Benitec Biopharma in a research report on Tuesday, September 16th. Finally, Citizens Jmp upped their price objective on Benitec Biopharma from $20.00 to $22.00 and gave the company a "market outperform" rating in a research note on Tuesday, November 4th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $26.25.
Check Out Our Latest Research Report on BNTC
Benitec Biopharma Company Profile
(
Get Free Report)
Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company's proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.
Benitec's lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
